

### **REMARKS**

In response to the Notice to Comply, Applicants herewith submit a Substitute Sequence Listing to replace the original corrupted Listing.

The original Sequence Listing included 206 sequences. However, the Sequence ID NO: 37 was inadvertently embedded into SEQ ID NO: 41. Therefore, the specification in reality included 207 sequences. Thus, Applicants have taken the original SEQ ID NO: 37 and inserted it into the correct place in the Sequence Listing thus correcting the listing to be in compliance with the sequences identified in the specification.

Upon review of the specification, Applicants further noticed additional Sequence Listing-related issues that have also been addressed in this amendment. Specifically, amendments to the Specification have been made to insert/correct the required SEQ ID NO identifiers associated with various listed sequences, as well as to incorporate by reference the Sequence Listing. Accordingly, Figure legends for Figures 6, 10 and 27 have been corrected. Of note, the identifier for SEQ ID NO: 199 relating to the indicated AVBV2 virus, was inadvertently left out from Figure 10B. Accordingly, Applicants have amended the Figure legend to incorporate the identifier for this sequence.

In view of the above, no new matter has been added by the amendments and their entry is respectfully requested.

Respectfully submitted,

Date: January 21, 2011

/Leena H. Karttunen Contarino/

**Customer No. 50607**

**NIXON PEABODY LLP**  
100 Summer Street  
Boston, MA 02110-2131  
Telephone: 617-345-1000  
Facsimile: 617-345-1300

LEENA H. KARTTUNEN CONTARINO  
Attorney for Applicant  
Registration No. 60,335

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 500850 for any such fees; and applicants hereby petition for any needed extension of time.